Promotions at Par Pharma as firm grows with acquisitions

US generics drugmaker Par Pharmaceutical (NYSE: PRX) has promoted Thomas Haughey to the role of president and Paul Campanelli to the role of chief operating officer of the company and its subsidiaries, effective immediately. Both executives will continue to report to Patrick LePore who will retain his title of chairman of the board and chief executive.

Mr LePore explained that, with the recently completed $410 acquisition of Anchen Pharmaceuticals (The Pharma Letter August 25) and the pending $37.6 million acquisition of Indian firm Edict (TPL May 24), Par is becoming a larger and more complex organization with three diverse locations and more than 300 additional employees. “These new challenges and opportunities require a president and chief operating officer to effectively manage the Company and its subsidiaries." Mr LePore continued.

Mr Haughey has served as chief administrative officer since 2008, executive vice president since 2006 and general counsel and secretary since joining Par in 2003.